Key facts
- This page summarizes Michelle Yanez's Form 4 filing for Telomir Pharmaceuticals, Inc. (TELO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Sep 2024, 13:37.
Michelle Yanez - 27 Aug 2024 Form 4 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TELO
- Reported as of
- 27 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Sep 2024, 13:37:18 UTC
- Prior SEC filing
- 29 Aug 2024
- Next SEC filing
- 10 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Yanez
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michelle Yanez filed Form 4 for Telomir Pharmaceuticals, Inc. (TELO) on 04 Sep 2024.
Change
- Previous filing in this sequence was filed on 29 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TELO
transaction
Derivative
Incentive Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 27 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $5.02
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024.
Footnote F2
The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50,000 stock options of such grant shall vest, respectively, on each of February 26, 2025, August 26, 2025, February 26, 2026 and August 26, 2026.